RAY1225
3 papers5 findings
- 1 lab
- Human trial3
Outcomes
3Body weight
downin humans3
3 studies
Body weight
downin humans3
RAY1225 decreases body weight in humans (-9.73% to -21.18% vs -2.96% for placebo).
“LS mean % changes for RAY1225 were -9.73% (3mg), -12.68% (6mg), -14.75% (9mg), -14.13% (12mg), -14.92% (15mg), and -21.18% (18mg), versus -2.96% for placebo (all p<0.001).”
Human trialoverweight or obese adults without diabetes24 weeksn = 231
ADA Scientific Sessions 2026 abstract7 Jun 2026
RAY1225 decreases body weight in humans (-10.06% (95% CI -11.63 to -8.49) vs -3.62% placebo).
“The mean percentage change in weight at week 24 was -10.06% (95% confidence interval, -11.63 to -8.49) with 3mg of RAY1225”
Human trial24 weeks
ADA Scientific Sessions 2025 abstract13 Jun 2025
RAY1225 decreases body weight in humans.
“All RAY1225 doses led to superior body weight reduction at week 24.”
Human trialin Chinese adults with type 2 diabetes24 weeksn = 132
ADA Scientific Sessions 2025 abstract13 Jun 2025
Systolic blood pressure
downin humans1
1 study
Systolic blood pressure
downin humans1
RAY1225 decreases systolic blood pressure in humans.
“Treatment also improved waist circumference, BMI, SBP, DBP, triglycerides, and uric acid vs. placebo.”
Human trialoverweight or obese adults without diabetes24 weeksn = 231
ADA Scientific Sessions 2026 abstract7 Jun 2026
HbA1c
downin humans1
1 study
HbA1c
downin humans1
RAY1225 decreases HbA1c in humans (-1.67% vs -0.23% (P<0.0001)).
“The reduction in HbA1c from baseline to week 24 was -1.67% (95% CI -1.91 to -1.42), -2.07% (-2.32 to -1.83), -2.24% (-2.78 to -1.70) in the 3 mg, 6mg and 9 mg, respectively, versus -0.23% (-0.47 to 0.01) with placebo (P<0.0001).”
Human trialin Chinese adults with type 2 diabetes24 weeksn = 132
ADA Scientific Sessions 2025 abstract13 Jun 2025